The dietary conversation is worth having, even when perfection isn't on the table.
For generations, the question of how diet shapes the fate of failing kidneys has resisted clean answers. A fifteen-year Israeli study now offers a measured but meaningful one: patients with chronic kidney disease who kept their daily protein intake below a moderate threshold were substantially less likely to need dialysis or suffer accelerating decline. The finding matters not because it overturns medical wisdom, but because it suggests that the achievable — not just the ideal — may still be worth pursuing.
- Millions of people with chronic kidney disease continue losing function even as newer drugs slow the damage, leaving a stubborn residual risk that pharmacology alone has not solved.
- A fifteen-year study of 530 Israeli patients found that simply staying below 1.0 gram of protein per kilogram of body weight daily cut the risk of needing dialysis by 35% — a number that carries real weight given dialysis's physical and financial toll.
- The threshold studied is notably more lenient than the strict low-protein targets most patients abandon, raising the possibility that clinicians have been discarding a useful tool because they set the bar too high.
- The study's retrospective design and limited use of modern kidney-protective drugs mean its findings are a signal, not a verdict — prospective trials in patients on current drug regimens are urgently needed to confirm whether the benefit holds.
For patients with slowly failing kidneys, dietary guidance has long been murky. A study from Yitzhak Shamir Medical Center in Zerifin, Israel, followed 530 adults with stage 3 or 4 chronic kidney disease over fifteen years, using urinary nitrogen excretion — a more objective measure than dietary recall — to assess daily protein intake. The dividing line was 1.0 gram of protein per kilogram of body weight per day.
Patients who stayed below that threshold were 23 percent less likely to reach a composite endpoint of severe kidney decline, dialysis initiation, or death. The most striking result was a 35 percent reduction in the risk of ever starting dialysis — a burden that is enormous for patients and health systems alike. Trends toward slower kidney decline and lower mortality appeared in the data but did not reach statistical significance on their own.
What gives the finding practical weight is what the threshold actually represents. The 1.0 gram cutoff is not the strict low-protein diet that guidelines have long recommended — that target, between 0.6 and 0.8 grams per kilogram, is one many patients cannot sustain. Lead author Ilia Beberashvili argued that moderate, achievable dietary changes paired with objective monitoring may be more realistic in clinical settings than rigid numerical goals.
The study arrives as SGLT2 inhibitors and GLP-1 receptor agonists have reshaped kidney disease management — yet patients on those drugs still lose function over time. The researchers contend that dietary protein regulation remains underused against what they call residual renal risk. They acknowledge the risk reduction they observed is smaller than what modern drug classes have shown, but argue it is not a number to dismiss.
Limitations are real: the study was retrospective, single-center, and concluded before the newer drug classes were widely prescribed — fewer than 10 percent of patients were on an SGLT2 inhibitor at baseline. Whether moderate protein restriction adds meaningful benefit on top of current pharmacotherapy remains unanswered. Beberashvili and colleagues are calling for prospective trials to settle that question. Until then, the study offers a quieter but still useful message: the dietary conversation in nephrology is worth having, even when the perfect target is out of reach.
For patients whose kidneys are slowly failing, the question of what to eat has never had a clean answer. A new study out of Israel suggests that one piece of that answer — how much protein to consume — may be simpler than the medical community has assumed.
Researchers at Yitzhak Shamir Medical Center in Zerifin followed 530 adults with stage 3 or 4 chronic kidney disease over fifteen years, tracking whether the amount of protein they ate each day made a measurable difference in how their kidneys held up. The patients were matched by propensity score to make the groups comparable, and their dietary protein intake was measured through 24-hour urinary nitrogen excretion — a more objective method than asking people to recall what they ate.
The dividing line the researchers drew was 1.0 gram of protein per kilogram of body weight per day. Those who stayed below that threshold were considered the low-intake group. Those above it were the comparison. The average patient was 67 years old, about a third were women, and roughly 40 percent had diabetes — a population that looks a lot like the people filling nephrology waiting rooms across the developed world.
Over the course of the study, patients eating less protein were 23 percent less likely to reach a composite endpoint that included a 50 percent or greater decline in kidney filtration rate, starting long-term dialysis, or dying from any cause. The most striking finding was narrower: those in the lower-protein group faced a 35 percent reduced risk of ever needing to begin dialysis. Trends toward slower kidney decline and lower mortality also appeared in the data, though neither reached statistical significance on its own.
What makes the finding notable is what the low-protein threshold actually represents. The 1.0 gram cutoff is not the strict low-protein diet that clinical guidelines have long recommended — that target sits between 0.6 and 0.8 grams per kilogram per day, a level that many patients, particularly those accustomed to meat-heavy diets, find difficult to sustain. The Israeli team was essentially asking whether a more moderate reduction, one that stops well short of the classic target, still offers meaningful protection. The answer, at least in this dataset, appears to be yes.
Lead author Ilia Beberashvili, MD, framed it in practical terms: moderate, achievable dietary changes combined with objective monitoring may be more realistic in everyday clinical settings than strict numerical targets. The implication is that clinicians who have given up on dietary counseling because patients can't hit the textbook goal might be leaving something on the table.
The study arrives at a moment when kidney disease management has been transformed by pharmacology. SGLT2 inhibitors and GLP-1 receptor agonists have become standard tools, and they work. But even patients on those medications continue to lose kidney function over time, accumulate protein in their urine, and carry elevated cardiovascular risk. The researchers argue that dietary protein regulation remains underused as a way to address what they call residual renal risk — the damage that drugs alone don't prevent.
The comparison to drug therapies is worth sitting with. The authors themselves acknowledged that the risk reduction they observed is smaller than what the newer pharmacological classes have demonstrated in trials. But they also argued that a 35 percent reduction in dialysis risk from a dietary change is not a number to dismiss, especially when dialysis carries enormous burdens — physical, logistical, and financial — for patients and health systems alike.
The study has real limitations. It was retrospective, conducted at a single center, and concluded in 2022, before SGLT2 inhibitors and GLP-1 agents were widely prescribed. Only about 10 percent of patients in the study were on an SGLT2 inhibitor at baseline, and fewer than 2 percent were on a GLP-1 agent. Whether moderate protein restriction adds the same benefit on top of modern drug regimens is a question this data cannot answer.
Beberashvili and colleagues are calling for prospective, interventional trials to define optimal protein targets across different CKD populations — and to test those targets in patients who are already on the drugs that have reshaped the field. Until that evidence exists, the Israeli study offers something more modest but still useful: a signal that the dietary conversation in nephrology clinics is worth having, even when perfection isn't on the table.
Citações Notáveis
Even moderate protein restriction — rather than strict targets — may still provide meaningful renoprotective benefits.— Ilia Beberashvili, MD, Yitzhak Shamir Medical Center
Moderate, achievable dietary changes combined with objective monitoring may be more feasible in real-world settings than strict dietary targets.— Beberashvili and co-authors, JAMA Network Open
A Conversa do Hearth Outra perspectiva sobre a história
What's the core thing this study is actually telling us?
That you don't have to hit the textbook target to get a benefit. Staying below one gram of protein per kilogram per day — which is still more than the classic low-protein diet recommends — was enough to cut dialysis risk by more than a third.
Why does protein intake matter for kidneys in the first place?
When you eat protein, your body produces nitrogen waste that the kidneys have to filter out. The more protein, the harder the kidneys work. For kidneys that are already struggling, that extra workload accelerates the damage.
The study ran for fifteen years. Does that length change how we should read it?
It adds weight to the findings, but it also means the world looked different when it started. Most of these patients weren't on the newer kidney-protective drugs that are now standard care. So we don't know how diet interacts with those medications.
Is there a tension between this study and the direction medicine has been moving — toward drugs rather than lifestyle?
That's exactly the tension the researchers are poking at. The drugs work, but they don't eliminate the problem. Patients on SGLT2 inhibitors still lose kidney function over time. The argument here is that diet addresses a gap the drugs leave open.
Why has dietary protein restriction been underused if the guidance has been there for years?
Partly because the evidence has been mixed — some studies showed benefit, others didn't. And partly because strict targets are genuinely hard for patients to maintain, especially in cultures where meat is central to the diet. Clinicians may have quietly stopped pushing it.
So the practical message is: aim for good enough rather than perfect?
Something like that. The researchers are saying that a moderate, sustainable reduction is better than a strict target that patients abandon after three months. Real-world adherence matters more than the ideal number on paper.
What would it take to actually change clinical practice based on this?
Prospective trials, ideally in patients already on modern drug regimens. This study is retrospective and from a single center. It's a strong signal, but it's not the kind of evidence that rewrites guidelines on its own.